Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis
Hyunwoo Lee(Princess Alexandra Hospital), Douglas L. Arnold(McGill University), Robert A. Brown(Montreal Neurological Institute and Hospital), Mark S. Freedman(University of Ottawa), Jacqueline T. Chen(Cleveland Clinic), Sridar Narayanan(Montreal Neurological Institute and Hospital), Harold Atkins(University of Ottawa)
Cited by 41
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
|American Journal of Ophthalmology|2006|551